Invesco Portfolio holdings
Invesco Ltd., founded in 1978 and headquartered in Atlanta, Georgia, is a global investment management firm managing hundreds of billions in assets across a diverse range of products, including mutual funds, exchange-traded funds (ETFs), and institutional portfolios. Known for its blend of active and passive investment strategies, Invesco serves individual investors, financial advisors, and institutions, with a strong presence in North America, Europe, and Asia, bolstered by acquisitions like OppenheimerFunds in 2019. The firm offers specialized solutions in equities, fixed income, real estate, and alternatives, leveraging its global research capabilities to cater to varying market needs. Invesco’s commitment to innovation and client-focused investing has solidified its reputation as a versatile player in the asset management industry.
Top Buys
| 1 |
HEICO Class A
HEI.A
|
+$884M |
| 2 |
Verizon
VZ
|
+$447M |
| 3 |
Exxon Mobil
XOM
|
+$388M |
| 4 |
ZTO Express
ZTO
|
+$285M |
| 5 |
AbbVie
ABBV
|
+$252M |
Top Sells
| 1 |
Qualcomm
QCOM
|
+$321M |
| 2 |
Avantor
AVTR
|
+$317M |
| 3 |
CDK
CDK Global, Inc.
CDK
|
+$256M |
| 4 |
Salesforce
CRM
|
+$233M |
| 5 |
Exelon
EXC
|
+$231M |
Sector Composition
| 1 | Technology | 18.16% |
| 2 | Healthcare | 13.37% |
| 3 | Financials | 12.69% |
| 4 | Industrials | 10.59% |
| 5 | Consumer Discretionary | 10.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3651
ImmunityBio
IBRX
$2.43B
| $145K | ﹤0.01% |
39,052
+3,344
| +9% | +$12.4K |
|
|
ROVR
3652
DELISTED
Rover Group, Inc. Class A Common Stock
ROVR
| $144K | ﹤0.01% |
+38,134
| New | +$144K |
|
|
AERI
3653
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $143K | ﹤0.01% |
19,077
-268
| -1% | -$2.01K |
|
3654
BRC Inc
BRCC
$183M
| $142K | ﹤0.01% |
+17,470
| New | +$142K |
|
3655
Design Therapeutics
DSGN
$331M
| $142K | ﹤0.01% |
+10,137
| New | +$142K |
|
3656
5E Advanced Materials
FEAM
$83.5M
| $142K | ﹤0.01% |
+506
| New | +$142K |
|
3657
Karyopharm Therapeutics
KPTI
$54.2M
| $141K | ﹤0.01% |
2,073
-30
| -1% | -$2.04K |
|
3658
Frontier Group Holdings
ULCC
$1.16B
| $141K | ﹤0.01% |
14,926
-337
| -2% | -$3.18K |
|
3659
Esperion Therapeutics
ESPR
$512M
| $140K | ﹤0.01% |
21,906
+7,801
| +55% | +$49.9K |
|
|
FEO
3660
DELISTED
First Trust/abrdn Emerging Opportunity Fund
FEO
| $138K | ﹤0.01% |
15,641
-419
| -3% | -$3.7K |
|
|
CBH
3661
DELISTED
Virtus Convertible & Income 2024 Target Term Fund
CBH
| $137K | ﹤0.01% |
15,940
-23,321
| -59% | -$200K |
|
3662
Mersana Therapeutics
MRSN
$35.1M
| $135K | ﹤0.01% |
1,168
-35
| -3% | -$4.05K |
|
|
AFMD
3663
DELISTED
Affimed
AFMD
| $134K | ﹤0.01% |
4,822
+491
| +11% | +$13.6K |
|
|
SVM
3664
Silvercorp Metals
SVM
$1.09B
| $134K | ﹤0.01% |
54,247
+4,269
| +9% | +$10.5K |
|
3665
Latham Group
SWIM
$951M
| $134K | ﹤0.01% |
19,222
+1,302
| +7% | +$9.08K |
|
3666
Credo Technology Group
CRDO
$25.8B
| $133K | ﹤0.01% |
11,348
-82,161
| -88% | -$963K |
|
3667
Kezar Life Sciences
KZR
$29.4M
| $133K | ﹤0.01% |
1,614
-39,100
| -96% | -$3.22M |
|
3668
Liquidia Corp
LQDA
$2.39B
| $133K | ﹤0.01% |
30,415
-227,307
| -88% | -$994K |
|
3669
Hydrofarm Holdings
HYFM
$15.2M
| $132K | ﹤0.01% |
3,807
+402
| +12% | +$13.9K |
|
3670
MiMedx Group
MDXG
$1.06B
| $132K | ﹤0.01% |
38,096
-3,887
| -9% | -$13.5K |
|
|
PFO
3671
Flaherty & Crumrine Preferred and Income Opportunity Fund
PFO
$124M
| $132K | ﹤0.01% |
+13,842
| New | +$132K |
|
3672
Microvast
MVST
$910M
| $131K | ﹤0.01% |
+58,572
| New | +$131K |
|
3673
Cantaloupe
CTLP
$794M
| $130K | ﹤0.01% |
23,230
-1,302
| -5% | -$7.29K |
|
|
INBX
3674
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $130K | ﹤0.01% |
11,477
+119
| +1% | +$1.35K |
|
3675
American Coastal Insurance
ACIC
$550M
| $129K | ﹤0.01% |
82,729
+8,649
| +12% | +$13.5K |
|